TY - JOUR
T1 - Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents
T2 - Cardiomyopathy and Beyond
AU - Moudgil, Rohit
AU - Yeh, Edward T.H.
N1 - Publisher Copyright:
© 2016 Canadian Cardiovascular Society.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Tremendous strides have been made in the treatment of various oncological diseases such that patients are surviving longer and are having better quality of life. However, the success has been tainted by the iatrogenic cardiac toxicities. This is especially concerning in the younger population who are facing cardiac disease such as heart failure in their 30s and 40s as the consequence of the anthracycline's side effects (used for childhood leukemia and lymphoma). This resulted in the awareness of cardiotoxic effects of anticancer drugs and emergence of a new discipline: oncocardiology. Since then, numerous anticancer drugs have been correlated to cardiomyopathy. Additionally, other cardiovascular effects have been identified, which includes but is not limited to myocardial infarction, thrombosis, hypertension, arrhythmias, and pulmonary hypertension. In this review we examine some of the anticancer agents that mitigate cardiotoxicity and present current knowledge of molecular mechanism(s). The aim of the review is to ignite awareness of emerging cardiotoxic effects as new generations of anticancer agents are being tested in clinical trials and introduced as part of the therapeutic armamentarium to our oncological patients.
AB - Tremendous strides have been made in the treatment of various oncological diseases such that patients are surviving longer and are having better quality of life. However, the success has been tainted by the iatrogenic cardiac toxicities. This is especially concerning in the younger population who are facing cardiac disease such as heart failure in their 30s and 40s as the consequence of the anthracycline's side effects (used for childhood leukemia and lymphoma). This resulted in the awareness of cardiotoxic effects of anticancer drugs and emergence of a new discipline: oncocardiology. Since then, numerous anticancer drugs have been correlated to cardiomyopathy. Additionally, other cardiovascular effects have been identified, which includes but is not limited to myocardial infarction, thrombosis, hypertension, arrhythmias, and pulmonary hypertension. In this review we examine some of the anticancer agents that mitigate cardiotoxicity and present current knowledge of molecular mechanism(s). The aim of the review is to ignite awareness of emerging cardiotoxic effects as new generations of anticancer agents are being tested in clinical trials and introduced as part of the therapeutic armamentarium to our oncological patients.
UR - http://www.scopus.com/inward/record.url?scp=84964240763&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964240763&partnerID=8YFLogxK
U2 - 10.1016/j.cjca.2016.01.027
DO - 10.1016/j.cjca.2016.01.027
M3 - Review article
C2 - 27117975
AN - SCOPUS:84964240763
SN - 0828-282X
VL - 32
SP - 863-870.e5
JO - Canadian Journal of Cardiology
JF - Canadian Journal of Cardiology
IS - 7
ER -